Robert Grubb to Digital Rectal Examination
This is a "connection" page, showing publications Robert Grubb has written about Digital Rectal Examination.
Connection Strength
0.584
-
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 05; 123(5):854-860.
Score: 0.158
-
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18; 104(2):125-32.
Score: 0.099
-
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26; 360(13):1310-9.
Score: 0.081
-
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008 Dec; 102(11):1524-30.
Score: 0.079
-
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology. 2006 Aug; 68(2):352-6.
Score: 0.068
-
Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol. 2012 Dec; 36(6):e401-6.
Score: 0.026
-
Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008 Dec; 19(10):1267-76.
Score: 0.019
-
Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. BJU Int. 2008 Jan; 101(2):181-5.
Score: 0.018
-
Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int. 2007 May; 99(5):1041-6.
Score: 0.018
-
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007 Apr; 99(4):775-9.
Score: 0.017